Signs You May Need Hormone Replacement Therapy: A Symptom Checklist and When to See a Provider

The most commonly cited signs you may need hormone replacement therapy (HRT) are menopause-related or hormone-decline symptoms that are persistent and severe enough to interfere with daily life, such as hot flashes, night sweats, disrupted sleep, vaginal dryness or painful intercourse, mood changes, brain fog, and reduced libido. None of these symptoms by themselves means HRT is right for you. They are signals that it may be reasonable to talk with a licensed provider, who can evaluate your history, weigh risks and benefits, and determine whether treatment is appropriate. This article is educational and is not medical advice.

What are the common signs of hormone decline?

Hormone shifts during perimenopause and menopause, and the more gradual hormone decline some people experience with age, can produce a broad and overlapping set of symptoms. According to patient education from The Menopause Society (formerly the North American Menopause Society), hormone therapy remains the most effective treatment for vasomotor symptoms such as hot flashes and night sweats, and for the genitourinary syndrome of menopause, which includes vaginal dryness, painful intercourse, and urinary symptoms. The widely cited threshold for action is when symptoms are severe enough to interfere with your daily life.

Symptom checklist

The table below summarizes commonly reported signs grouped by category. Experiencing one or several of these does not confirm that you have a hormone deficiency, and it does not mean HRT is indicated. Use it as a starting point for a conversation with a qualified clinician.

Category	Commonly reported signs
Vasomotor	Hot flashes, night sweats, flushing
Genitourinary	Vaginal dryness, painful intercourse, recurrent urinary symptoms
Sleep and energy	Trouble sleeping, fatigue, low energy
Mood and cognition	Mood changes, irritability, brain fog, memory concerns
Cycle changes (perimenopause)	Irregular or skipped periods
Sexual health	Low libido, reduced sexual interest
Men (testosterone decline)	Reduced libido, erectile changes, fatigue, depressed mood, reduced muscle mass, poor concentration

Many of these symptoms overlap with thyroid conditions, depression, anemia, medication side effects, and other issues, which is one reason a provider evaluation matters before assuming hormones are the cause.

When should you see a provider?

A reasonable time to seek evaluation is when symptoms are bothersome, persistent, or interfering with your sleep, relationships, work, or quality of life. Sudden or unusual symptoms, unexplained vaginal bleeding, or any concerning new finding warrant prompt medical attention rather than self-treatment. Because hormone-related symptoms can mimic other conditions, a provider can help sort out the likely cause and discuss whether HRT, non-hormonal options, or further testing makes sense for you.

What does evaluation for HRT involve?

For women older than roughly 45 with typical menopausal symptoms, menopause is generally diagnosed clinically, and routine baseline hormone blood testing is often not required to make the diagnosis, according to ACOG patient guidance. A typical evaluation usually includes a symptom and menstrual history, a personal and family history of breast cancer, blood clots, stroke, and heart disease, a blood pressure check, and a discussion of the potential risks and benefits for your situation.

The pathway is different for men. The American Urological Association guideline indicates that diagnosing testosterone deficiency generally requires both symptoms and biochemistry, specifically a total testosterone below 300 ng/dL confirmed on at least two separate early-morning blood tests. A single blood test alone is generally not considered sufficient to diagnose or justify treatment. In short, menopause is often a clinical diagnosis, while a low-testosterone diagnosis is lab-confirmed, so the two workups should not be conflated.

Bioidentical versus conventional HRT: what is the real distinction?

A common misconception is that “bioidentical” means “natural” or “unregulated” and that conventional HRT means “synthetic.” That framing is misleading. Many FDA-approved products are themselves bioidentical, including estradiol, micronized progesterone, and transdermal estradiol. According to ACOG clinical consensus, the meaningful distinction is FDA-approved versus compounded. The FDA does not review or approve compounded preparations for safety, quality, or effectiveness.

ACOG’s clinical consensus indicates that compounded bioidentical menopausal hormone therapy should not be routinely prescribed when FDA-approved formulations exist, and that FDA-approved menopausal hormone therapies are recommended over compounded bioidentical products. The same guidance notes that saliva hormone testing to guide dosing is not recommended. Separately, the National Academies of Sciences, Engineering, and Medicine (NASEM) provided the FDA its analysis of compounded bioidentical hormone therapy on July 1, 2020 and recommended that compounded preparations of these products receive closer review. NASEM issued that recommendation to the FDA and its advisory process; the FDA did not itself enact a ban in that report.

What are the risks and benefits of HRT?

Benefits and risks vary by the specific person, the formulation, the route of delivery, and the timing of treatment, which is why decisions must be individualized. On the benefit side, professional sources describe hormone therapy as the most effective treatment for vasomotor and genitourinary symptoms, along with a reduction in bone fractures. On the risk side, the American Cancer Society notes that combined estrogen-plus-progestogen therapy is associated with a small increased risk of breast cancer with longer-duration use, and that estrogen-alone therapy in a person with a uterus raises endometrial cancer risk, which is why a progestogen is typically added. Risks can also differ by delivery route and timing, so these tradeoffs are best reviewed individually with a provider.

Regulatory framing has been changing. On November 10, 2025, the U.S. Department of Health and Human Services announced, at a press conference featuring HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary, that the FDA is initiating removal of certain boxed (so-called black box) warning language from menopausal hormone therapy products. The action removes references to cardiovascular disease, breast cancer, and probable dementia from the boxed warning. Importantly, it does not remove every warning: per the FDA, “The FDA is not seeking to remove the boxed warning for endometrial cancer for systemic estrogen-alone products,” so that warning is retained. On February 12, 2026, the FDA approved labeling changes to six menopausal hormone therapy products as a first batch implementing that action, with the broader rollout ongoing.

The FDA also cites a timing consideration sometimes called the timing hypothesis. According to the FDA, “Randomized studies show that women who initiate HRT within 10 years of the onset of menopause (generally before age 60) have a reduction in all-cause mortality and fractures.” That finding applies to that specific younger, recently menopausal window and should not be read as evidence that HRT is an anti-aging or longevity treatment for everyone. The agency has noted that the original boxed warnings followed a Women’s Health Initiative study in which the average participant age was 63, more than a decade past the average age of menopause onset, and in which the breast-cancer finding was described as a “statistically non-significant increase.”

Who is not a candidate for HRT?

HRT is not appropriate for everyone, and some conditions are generally considered contraindications to systemic estrogen therapy. Based on clinical reference guidance, people who are generally not candidates include those with a known, suspected, or prior history of estrogen-sensitive breast cancer or another estrogen-dependent cancer such as endometrial cancer, unexplained vaginal bleeding, a history of blood clots such as DVT or PE, a history of stroke, active liver disease, or known or suspected pregnancy. Coronary heart disease and uncontrolled high blood pressure are also commonly treated as cautions. These decisions must be individualized, and a licensed provider weighs your full history before any prescription is considered.

Frequently asked questions

Does having these symptoms mean I definitely need HRT?

No. These symptoms are signals that a conversation with a licensed provider may be reasonable, not a diagnosis. Many of these symptoms overlap with thyroid conditions, depression, anemia, and medication effects, so a clinician evaluates the likely cause and whether hormone therapy, non-hormonal options, or further testing fits your situation. Individual results vary.

Is bioidentical hormone therapy safer than conventional HRT?

Not necessarily. “Bioidentical” describes the molecular structure, not the safety profile, and many FDA-approved products are bioidentical. Professional guidance draws the meaningful line between FDA-approved and compounded products, because the FDA does not review compounded preparations for safety, quality, or effectiveness, and recommends FDA-approved options over compounded bioidentical products when available.

Do I need a blood test to know if I need HRT?

It depends. For women older than about 45 with typical menopausal symptoms, menopause is generally a clinical diagnosis and routine hormone blood testing is often not required. For men, diagnosing low testosterone generally requires symptoms plus a total testosterone below 300 ng/dL confirmed on two separate early-morning blood tests. A provider determines what testing, if any, is appropriate.

Did the FDA remove all the warnings from HRT?

No. The action announced by HHS on November 10, 2025 and implemented in a first batch of six products on February 12, 2026 removes references to cardiovascular disease, breast cancer, and probable dementia from the boxed warning. The boxed warning for endometrial cancer on systemic estrogen-alone products is retained, and the rollout across products is ongoing.